High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Sponsor
Taizhou Hospital
Study ID
NCT06319950
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Lung Cancer, Nonsmall Cell

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.

Key Dates

Start date
Apr 1, 2024
Status verified
Mar 2024
Primary completion
Dec 30, 2026
Completion
Dec 30, 2026

Study Design

Enrollment
255 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: High-dose Furmonertinib group
    Furmonertinib, 160mg po qd
  • Active Comparator: Osimertinib group
    Osimertinib, 80mg po qd

Primary Outcome Measure

progression free survival(PFS) [ Time Frame: 5 years from first patient randomized. ]

Central Contacts

Related Studies